Published in Chest on February 01, 2012
Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.88
Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med (2014) 4.58
Direct oral anticoagulants: integration into clinical practice. Postgrad Med J (2014) 1.40
Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.31
Which Fixation Device is Preferred for Surgical Treatment of Intertrochanteric Hip Fractures in the United States? A Survey of Orthopaedic Surgeons. Clin Orthop Relat Res (2015) 1.18
Re-evaluation of low intensity pulsed ultrasound in treatment of tibial fractures (TRUST): randomized clinical trial. BMJ (2016) 1.14
Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V. Thromb J (2015) 1.09
Thromboprophylaxis only during hospitalisation in fast-track hip and knee arthroplasty, a prospective cohort study. BMJ Open (2013) 1.02
Venous thromboembolism after total joint arthroplasty: results from a Japanese multicenter cohort study. Arthritis Res Ther (2014) 0.99
Aspirin for elective hip and knee arthroplasty: a multimodal thromboprophylaxis protocol. Int Orthop (2012) 0.95
How to Write Up Your Quality Improvement Initiatives for Publication. J Grad Med Educ (2016) 0.95
Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know. J Thromb Thrombolysis (2013) 0.93
Prevention of venous thromboembolism, 2nd edition: Korean Society of Thrombosis and Hemostasis Evidence-based Clinical Practice Guidelines. J Korean Med Sci (2014) 0.92
Incidence of deep vein thrombosis after major lower limb orthopedic surgery: analysis of a nationwide claim registry. Yonsei Med J (2015) 0.91
Retrospective comparison of three thromboprophylaxis agents, edoxaban, fondaparinux, and enoxaparin, for preventing venous thromboembolism in total knee arthroplasty. Int Orthop (2013) 0.89
The efficacy and safety of rivaroxaban for venous thromboembolism prophylaxis after total hip and total knee arthroplasty. Thrombosis (2013) 0.87
Pediatric orthopaedic lower extremity trauma and venous thromboembolism. J Child Orthop (2015) 0.87
Thromboembolic prophylaxis in total joint arthroplasty. Thrombosis (2012) 0.87
Management of Deep Vein Thrombosis (DVT) Prophylaxis in Trauma Patients. Bull Emerg Trauma (2016) 0.86
Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs (2014) 0.86
An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes. J Am Heart Assoc (2013) 0.86
Prevention of venous thromboembolism in patients undergoing bariatric surgery. Vasc Health Risk Manag (2015) 0.85
The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery. Expert Rev Hematol (2013) 0.84
Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence. Adv Hematol (2015) 0.84
Anti-phospholipid antibodies in patients undergoing total joint replacement surgery. Thrombosis (2012) 0.84
Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications. Drugs (2014) 0.83
Incidence of venous thromboembolism and hemorrhage related safety studies of preoperative anticoagulation therapy in hip fracture patients undergoing surgical treatment: a case-control study. BMC Musculoskelet Disord (2016) 0.83
Aspirin: an alternative for pulmonary embolism prophylaxis after arthroplasty? Clin Orthop Relat Res (2014) 0.83
The role of anticoagulation clinics in the era of new oral anticoagulants. Thrombosis (2012) 0.82
Thromboprophylaxis is associated with reduced post-hospitalization venous thromboembolic events in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol (2014) 0.82
Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review. Ther Clin Risk Manag (2015) 0.82
Clinical outcomes of distal femoral fractures in the geriatric population using locking plates with a minimally invasive approach. Geriatr Orthop Surg Rehabil (2013) 0.82
Incidence rate of symptomatic venous thromboembolic disease in patients from a medical care program in Buenos Aires, Argentina: a prospective cohort. Thromb J (2013) 0.82
A Survey of the Knowledge of Venous Thromboembolism Prophylaxis among the Medical Staff of Intensive Care Units in North China. PLoS One (2015) 0.81
Guidance for the prevention and treatment of the post-thrombotic syndrome. J Thromb Thrombolysis (2016) 0.81
Complications following hip arthroscopy: a retrospective review of the McMaster experience (2009-2012). Can J Surg (2013) 0.81
Effectiveness of a novel and scalable clinical decision support intervention to improve venous thromboembolism prophylaxis: a quasi-experimental study. BMC Med Inform Decis Mak (2012) 0.80
Venous Thromboembolism Following Hip and Knee Replacement Arthroplasty in Korea: A Nationwide Study Based on Claims Registry. J Korean Med Sci (2015) 0.80
Practical management of new oral anticoagulants after total hip or total knee arthroplasty. Musculoskelet Surg (2013) 0.80
Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2016) 0.80
Expanding use of new oral anticoagulants. F1000Prime Rep (2014) 0.80
Estimated Prevalence of Venous Thromboembolism in Iran: Prophylaxis Still an Unmet Challenge. Tanaffos (2015) 0.79
Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. Vasc Health Risk Manag (2014) 0.79
A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery. Thromb J (2015) 0.79
Appropriateness of Dabigatran and Rivaroxaban Prescribing for Hospital Inpatients. Can J Hosp Pharm (2016) 0.79
Thromboprophylaxis for deep vein thrombosis and pulmonary embolism after total joint arthroplasty in a low incidence population. Knee Surg Relat Res (2013) 0.79
Incidence of venous thromboembolism after elective knee arthroscopic surgery: a historical cohort study. J Thromb Haemost (2013) 0.79
II Italian intersociety consensus statement on antithrombotic prophylaxis in orthopaedics and traumatology: arthroscopy, traumatology, leg immobilization, minor orthopaedic procedures and spine surgery. J Orthop Traumatol (2012) 0.79
A cohort study on the incidence and outcome of pulmonary embolism in trauma and orthopedic patients. BMC Med (2014) 0.79
Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis. J Arthroplasty (2016) 0.78
Effects of a Foot Pump on the Incidence of Deep Vein Thrombosis After Total Knee Arthroplasty in Patients Given Edoxaban: A Randomized Controlled Study. Medicine (Baltimore) (2016) 0.78
Analysis of Risk Factors for Lower-limb Deep Venous Thrombosis in Old Patients after Knee Arthroplasty. Chin Med J (Engl) (2015) 0.78
Thromboprophylaxis and orthopaedic surgery: options and current guidelines. Malays J Med Sci (2014) 0.78
Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery. Vasc Health Risk Manag (2013) 0.78
Patients' perception about risks and benefits of antithrombotic treatment for the prevention of venous thromboembolism (VTE) after orthopedic surgery: a qualitative study. BMC Musculoskelet Disord (2015) 0.78
Transitions of care in anticoagulated patients. J Multidiscip Healthc (2013) 0.78
Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran. Vasc Health Risk Manag (2015) 0.78
Thromboembolic and major bleeding events in relation to perioperative bridging of vitamin K antagonists in 649 fast-track total hip and knee arthroplasties. Acta Orthop (2016) 0.77
The use of warfarin for DVT prophylaxis following hip and knee arthroplasty: how often are patients within their target INR range? J Arthroplasty (2014) 0.77
Venous thromboembolism following major orthopedic surgery. Maedica (Buchar) (2013) 0.77
Changes of thrombelastography in patients undergoing elective primary total knee and total hip replacement with low molecular heparin prophylaxis. J Orthop Surg Res (2014) 0.77
Surgical site infections and other postoperative complications following prophylactic anticoagulation in total joint arthroplasty. PLoS One (2014) 0.77
The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery - subgroup analyses from 17,701 patients in the XAMOS study. Vasc Health Risk Manag (2016) 0.77
Algorithm for anticoagulation management in geriatric hip fracture patients--Surgeons save Blood. Z Gerontol Geriatr (2014) 0.77
The Effect of Low Molecular Weight Heparins on Fracture Healing. Open Orthop J (2015) 0.77
Pharmacological prevention of venous thromboembolism in orthopaedic surgery. Clin Cases Miner Bone Metab (2014) 0.77
Effect of postoperative use of nasal oxygen catheter supplementation in wound healing following total knee arthroplasty. Clinics (Sao Paulo) (2014) 0.77
Comparative effectiveness of venous thromboembolism prophylaxis options for the patient undergoing total hip and knee replacement: a network meta-analysis. J Thromb Haemost (2016) 0.77
Stress ulcer prophylaxis, thromboprophylaxis and coagulation management in patients with hip fractures. Wien Med Wochenschr (2013) 0.76
Low frequency of symptomatic venous thromboembolism after multiligamentous knee reconstruction with thromboprophylaxis. Clin Orthop Relat Res (2014) 0.76
Real-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patients. Curr Orthop Pract (2015) 0.76
Concept of a point of care test to detect new oral anticoagulants in urine samples. Thromb J (2013) 0.76
Dabigatran etexilate for thromboprophylaxis in over 5000 hip or knee replacement patients in a real-world clinical setting. Thromb J (2016) 0.76
Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. Br J Clin Pharmacol (2014) 0.76
Comparative safety and efficacy of antithrombotics in the management of venous thromboembolism after knee or hip replacement surgery: focus on rivaroxaban. Clin Pharmacol (2013) 0.76
Dental management of patients taking novel oral anticoagulants (NOAs): Dabigatran. J Clin Exp Dent (2017) 0.75
Comparison of Enoxaparin and Rivaroxaban in Balance of Anti-Fibrinolysis and Anticoagulation Following Primary Total Knee Replacement: A Pilot Study. Med Sci Monit (2017) 0.75
Intermittent Pneumatic Compression for the Prevention of Venous Thromboembolism after Total Hip Arthroplasty. Clin Orthop Surg (2017) 0.75
Managing patients taking edoxaban in dentistry. J Clin Exp Dent (2017) 0.75
Idraparinux or idrabiotaparinux for long-term venous thromboembolism treatment: a systematic review and meta-analysis of randomized controlled trials. PLoS One (2013) 0.75
Fatal Pulmonary Embolism following Achilles Tendon Repair: A Case Report and a Review of the Literature. Case Rep Orthop (2013) 0.75
Thromboprophylaxis with fondaparinux in high-risk postoperative patients with renal insufficiency. Thromb Res (2013) 0.75
The incidence of deep vein thrombosis and pulmonary embolism after fracture of the tibia: An analysis of the National Trauma Databank. J Clin Orthop Trauma (2017) 0.75
Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. World J Gastroenterol (2017) 0.75
Venous Thromboembolism (VTE) Prophylaxis for Hip and Knee Arthroplasty: Changing Trends. Curr Rev Musculoskelet Med (2014) 0.75
Biomarkers of Coagulation and Fibrinolysis during Cemented Total Hip Arthroplasty with Pre- versus Postoperative Start of Thromboprophylaxis. Thrombosis (2013) 0.75
Apixaban. Hosp Pharm (2013) 0.75
CORR Insights®: Symptomatic pulmonary embolus after joint arthroplasty: stratification of risk factors. Clin Orthop Relat Res (2013) 0.75
Patient compliance with new oral anticoagulants after major orthopaedic surgery: rivaroxaban and dabigatran compared with subcutaneous injection of fondaparinux. Joints (2017) 0.75
Venous haemodynamics of Jet Impulse Technology within a lower limb fibreglass cast: a randomized controlled trial. JRSM Open (2017) 0.75
Prevention of Hospital-Acquired Venous Thromboembolism in Children: A Review of Published Guidelines. Front Pediatr (2017) 0.75
Initial Preoperative Management of Geriatric Hip Fractures. Geriatr Orthop Surg Rehabil (2016) 0.75
Thromboembolic disease in patients with rheumatoid arthritis undergoing joint arthroplasty: Update on prophylaxes. World J Orthop (2014) 0.75
Intermittent pneumatic compression devices combined with anticoagulants for prevention of symptomatic deep vein thrombosis after total knee arthroplasty: a pilot study. Ther Clin Risk Manag (2017) 0.75
Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 16.17
Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med (2000) 7.62
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet (2009) 6.83
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med (2008) 6.32
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med (2008) 6.00
Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med (1988) 5.81
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med (2010) 5.59
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet (2007) 5.41
Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet (2000) 4.38
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med (2001) 4.33
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost (2007) 3.66
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet (2010) 3.29
Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med (2009) 2.90
Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial. Ann Intern Med (2008) 2.85
A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med (1993) 2.76
Reducing the risk of venous thromboembolism in patients admitted to hospital: summary of NICE guidance. BMJ (2010) 2.64
Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost (2003) 2.62
Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med (1998) 2.58
Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med (1996) 2.55
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med (2001) 2.54
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation (2006) 2.54
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost (2011) 2.53
Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg (1988) 2.52
Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet (2001) 2.46
Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-leg immobilization. Cochrane Database Syst Rev (2008) 2.37
Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med (2001) 2.37
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty (2008) 2.30
Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the post-arthroplasty screening study. A randomized, controlled trial. Ann Intern Med (1997) 2.28
Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. JAMA (1992) 2.27
Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med (2003) 2.22
Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med (1996) 2.22
Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med (2002) 2.16
Epidemiology of venous thromboembolism in Asian patients undergoing major orthopedic surgery without thromboprophylaxis. The SMART study. J Thromb Haemost (2005) 2.03
Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. J Bone Joint Surg Am (2001) 1.87
Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am (1999) 1.84
Thrombosis prevention after total hip arthroplasty: a prospective, randomized trial comparing a mobile compression device with low-molecular-weight heparin. J Bone Joint Surg Am (2010) 1.79
Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism in high-risk patients. Cochrane Database Syst Rev (2008) 1.79
Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin) Thromb Haemost (1997) 1.73
The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost (2007) 1.73
Graded compression stockings for prevention of deep-vein thrombosis after hip and knee replacement. J Bone Joint Surg Br (1996) 1.71
Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am (2001) 1.71
A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med (1986) 1.67
Prevention of thromboembolism in 190 hip arthroplasties. Comparison of LMW heparin and placebo. Acta Orthop Scand (1991) 1.66
Aspirin prophylaxis of venous thromboembolism after total hip replacement. N Engl J Med (1977) 1.65
Perioperative low-molecular-weight heparin. Is it effective and safe. J Bone Joint Surg Br (1995) 1.60
Risk factors for clinically relevant pulmonary embolism and deep venous thrombosis in patients undergoing primary hip or knee arthroplasty. Anesthesiology (2003) 1.60
BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost (2005) 1.60
Frequency and timing of clinical venous thromboembolism after major joint surgery. J Bone Joint Surg Br (2006) 1.56
Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement. JAMA (1990) 1.55
Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med (2000) 1.53
Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system. J Bone Joint Surg Br (1999) 1.52
Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement. A prospective, randomized trial. J Bone Joint Surg Am (1998) 1.51
Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. Arch Intern Med (2000) 1.48
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost (2006) 1.44
Low risk of thromboembolic complications after fast-track hip and knee arthroplasty. Acta Orthop (2010) 1.44
Anticoagulant prophylaxis, thromboembolism and mortality in elderly patients with hip fractures. A controlled clinical trial. Acta Chir Scand (1967) 1.42
Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression. Br Med J (1980) 1.37
Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med (2000) 1.34
Mechanical prophylaxis of deep-vein thrombosis after total hip replacement a randomised clinical trial. J Bone Joint Surg Br (2004) 1.33
Randomized trial of graded compression stockings for prevention of deep-vein thrombosis after acute stroke. QJM (2000) 1.27
Why does prophylaxis with external pneumatic compression for deep vein thrombosis fail? Am J Surg (1992) 1.24
Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg (2005) 1.19
Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. J Bone Joint Surg Am (1997) 1.16
Prevention of venous thromboembolism after knee arthroscopy with low-molecular weight heparin (reviparin): Results of a randomized controlled trial. Arthroscopy (2001) 1.15
Risk factors for venous thromboembolism in patients undergoing total hip replacement and receiving routine thromboprophylaxis. J Bone Joint Surg Am (2010) 1.13
Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery. A placebo controlled study. J Bone Joint Surg Br (1991) 1.10
Prevention of deep-vein thrombosis in ambulatory arthroscopic knee surgery: A randomized trial of prophylaxis with low--molecular weight heparin. Arthroscopy (2002) 1.10
Preventing venous thromboembolism in elderly patients with hip fractures: studies of low-dose heparin, dipyridamole, aspirin, and flurbiprofen. Br Med J (1977) 1.10
A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty. J Thromb Haemost (2010) 1.08
Warfarin sodium in prevention of deep venous thrombosis and pulmonary embolism in patients with fractured neck of femur. Lancet (1976) 1.07
Controlled trial of platelet anti-aggregating agents and subcutaneous heparin in prevention of postoperative deep vein thrombosis in high risk patients. Haemostasis (1975) 1.06
Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin. J Orthop Sci (2008) 1.06
Prevention of deep vein thrombosis after major knee surgery--a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost (1992) 1.05
Pulmonary embolism prophylaxis with inferior vena cava filters in trauma patients: a systematic review using the meta-analysis of observational studies in epidemiology (MOOSE) guidelines. J Thromb Thrombolysis (2011) 1.04
Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients. Int Orthop (2007) 1.03
Rapid-inflation intermittent pneumatic compression for prevention of deep venous thrombosis. J Bone Joint Surg Am (2007) 1.01
Compliance with sequential compression device prophylaxis in at-risk trauma patients: a prospective analysis. Am Surg (2002) 1.00
Intermittent pneumatic compression and deep vein thrombosis prevention. A meta-analysis in postoperative patients. Thromb Haemost (2005) 0.99
A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch Intern Med (1989) 0.98
The effectiveness of intermittent plantar venous compression in prevention of deep venous thrombosis after total hip arthroplasty. J Arthroplasty (1993) 0.97
Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study. Thromb Res (1998) 0.95
Prophylaxis of thromboembolic disease and platelet-related changes following total hip replacement: a comparative study of aspirin and heparin-dihydroergotamine. Thromb Haemost (1986) 0.94
[Prevention of thromboembolism using acetylsalicylic acid in the surgery of hip-joint proximal fractures]. Monatsschr Unfallheilkd Versicher Versorg Verkehrsmed (1974) 0.94
Prevention of deep-vein thrombosis after total hip and knee replacement. Low-molecular-weight heparin in combination with intermittent pneumatic compression. J Bone Joint Surg Br (2004) 0.94
Intermittent pneumatic compression versus coumadin. Prevention of deep vein thrombosis in lower-extremity total joint arthroplasty. Clin Orthop Relat Res (1991) 0.93
Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy. Cochrane Database Syst Rev (2008) 0.93
Effectiveness of pneumatic leg compression devices for the prevention of thromboembolic disease in orthopaedic trauma patients: a prospective, randomized study of compression alone versus no prophylaxis. J Orthop Trauma (1995) 0.93
A comparison of intermittent calf compression and enoxaparin for thromboprophylaxis in total hip replacement. A pilot study. Int Orthop (1996) 0.92
Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: a systematic review. Arch Intern Med (2003) 0.92
A prospective randomized study on the use of nadroparin calcium in the prophylaxis of thromboembolism in Korean patients undergoing elective total hip replacement. Int Orthop (1997) 0.91
Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. Circulation (2009) 0.90
Prospective randomized trial of sequential compression devices vs low-dose warfarin for deep venous thrombosis prophylaxis in total hip arthroplasty. J Arthroplasty (1991) 0.90
Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant. Arch Intern Med (2002) 0.90
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med (2008) 31.57
Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 16.17
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 11.84
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med (2015) 10.86
Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science (2005) 9.04
Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med (2001) 8.95
ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med (2003) 8.83
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94
Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.12
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2013) 5.56
Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med (2009) 5.48
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet (2007) 5.41
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol (2007) 5.36
Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med (2010) 5.23
Evaluation of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 4.49
Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 4.29
Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood (2008) 4.06
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01
Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med (2003) 3.96
Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 3.86
The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.74
Evolution of adverse changes in stored RBCs. Proc Natl Acad Sci U S A (2007) 3.58
Interventional pulmonary procedures: Guidelines from the American College of Chest Physicians. Chest (2003) 3.55
Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. JAMA (2013) 3.48
Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 3.46
Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.36
Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest (2007) 3.36
Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.31
Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer (2007) 3.27
Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet (2006) 3.25
Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med (2006) 3.11
Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med (2012) 3.04
Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med (2015) 3.03
An Official ATS/AACN/ACCP/ESICM/SCCM Policy Statement: Responding to Requests for Potentially Inappropriate Treatments in Intensive Care Units. Am J Respir Crit Care Med (2015) 2.86
Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 2.83
Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 2.74
RNA aptamers as reversible antagonists of coagulation factor IXa. Nature (2002) 2.73
Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 2.72
Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation (2013) 2.72
D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med (2015) 2.63
Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 2.60
Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 2.56
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation (2006) 2.54
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost (2011) 2.53
Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 2.50
Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 2.50
Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 2.47
Grades of recommendation for antithrombotic agents. Chest (2001) 2.44
Venous thromboembolism: a public health concern. Am J Prev Med (2010) 2.37
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty (2008) 2.30
Correlation between the knee adduction torque and medial contact force for a variety of gait patterns. J Orthop Res (2007) 2.27
Comparison of characteristics from White- and Black-Americans with venous thromboembolism: a cross-sectional study. Am J Hematol (2010) 2.26
Practice parameters for the use of portable monitoring devices in the investigation of suspected obstructive sleep apnea in adults. Sleep (2003) 2.21
Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer (2005) 2.20
Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review. Ann Intern Med (2013) 2.15
Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology (2014) 2.12
A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: one- to eight-year outcomes. J Am Coll Cardiol (2003) 2.10
White paper on CTSA consortium role in facilitating comparative effectiveness research: September 23, 2009 CTSA consortium strategic goal committee on comparative effectiveness research. Clin Transl Sci (2010) 2.09
The solitary pulmonary nodule. Chest (2003) 2.09
Selective D-dimer testing for diagnosis of a first suspected episode of deep venous thrombosis: a randomized trial. Ann Intern Med (2013) 2.09
Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 2.06
Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol (2006) 2.03
Diagnosis and management of lung cancer executive summary: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest (2007) 2.02
Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 2.00
Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest (2007) 1.99